Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?

Gustavo Saposnik*, Jorge Maurino, Angel P. Sempere, Maria A. Terzaghi, Maria Pia Amato, Xavier Montalban

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

2 Cites (Scopus)

Resum

Conferences traditionally play an important role in the ongoing medical education of healthcare professionals. We assessed the influence of attending the ECTRIMS congress on therapeutic decision-making in multiple sclerosis (MS) care. A non-interventional, cross-sectional study involving 96 neurologists was conducted. Treatment escalation when therapeutic goals were unmet and management errors related to tolerability and safety scenarios of MS therapies were tested using different case-scenarios. Attendance at ECTRIMS was associated with an increase likelihood of treatment escalation in the presence of clinical progression (cognitive decline) and radiological activity (OR 2.44; 95% CI 1.06–5.82) and lower number of management errors (OR 0.26; 95% CI 0.07–0.98). Attendance at ECTRIMS may facilitate therapeutic decisions and reduction in management errors in MS care.

Idioma originalEnglish
RevistaMultiple Sclerosis Journal - Experimental, Translational and Clinical
Volum5
Número1
Data online anticipada18 de març 2019
DOIs
Estat de la publicacióPublicada - 2019

Fingerprint

Navegar pels temes de recerca de 'Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?'. Junts formen un fingerprint únic.

Com citar-ho